Fluorine 18 MK 6240

Drug Profile

Fluorine 18 MK 6240

Alternative Names: [18F]MK 6240; [18F]MNI-946; [3H]MK 6240; [F-18]MK-6240; Fluorine-18-MK6240; MK-6240

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Cerveau Technologies; Janssen Pharmaceuticals; Merck Sharp & Dohme; Washington University School of Medicine
  • Class Imaging agents; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Research Neurodegenerative disorders

Most Recent Events

  • 23 Oct 2017 Cerveau Technologies licenses Fluorine 18 MK 6240 to AbbVie for use as a biomarker in clinical trials of drugs for Alzheimer’s disease
  • 19 Oct 2017 Cerveau Technologies enters into a research collaboration with Columbia University Medical Center for neurodegenerative diseases
  • 16 Oct 2017 Cerveau Technologies and Janssen Pharmaceuticals agree to co-develop Fluorine 18 MK 6240 for Neurodegenerative disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top